Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer
Status:
Terminated
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Primary objective:
To determine the brain response rate of Lipo-Dox in breast cancer patients with brain
metastasis
Secondary objectives:
1. To determine the overall objective response rate (ORR)
2. To determine the progression free survival, and duration of objective response
3. To evaluate the overall survival (OS)
4. To assess the safety profiles
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins